Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
- Conditions
- Adenovirus
- Registration Number
- NCT02596997
- Lead Sponsor
- Chimerix
- Brief Summary
Provide patients with serious AdV infection or disease access to treatment with BCV.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
- Confirmed serious AdV infection based on clinical symptoms and laboratory testing showing AdV in the blood or other bodily fluids
- Able to swallow medication, either tablet or liquid
- Previous dosing with Brincidofovir
- If female, not pregnant or trying to become pregnant
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (46)
University of Arkansas Medical Center
🇺🇸Little Rock, Arkansas, United States
Children's Hospital LA
🇺🇸Los Angeles, California, United States
UCLA Medical Center
🇺🇸Los Angeles, California, United States
Children's Hospital of Orange County
🇺🇸Orange, California, United States
Pediatric Stem Cell Transplantation Stanford University
🇺🇸Palo Alto, California, United States
Stanford University
🇺🇸Palo Alto, California, United States
UC San Diego Moores Cancer center
🇺🇸San Diego, California, United States
University of California San Francisco Benioff Children's Hospital
🇺🇸San Francisco, California, United States
Children's Hospital Colorado
🇺🇸Aurora, Colorado, United States
Children's National Medical Center
🇺🇸Washington, District of Columbia, United States
Scroll for more (36 remaining)University of Arkansas Medical Center🇺🇸Little Rock, Arkansas, United States